Katherine Stueland - 06 Mar 2026 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Bridget Brown, Attorney-in-Fact
Issuer symbol: WGS
Transactions as of: 06 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 09 Mar 2026, 07:54:54 UTC
Previous filing: 05 Mar 2026
Next filing: 11 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Stueland Katherine	CHIEF EXECUTIVE OFFICER, Director	C/O GENEDX HOLDINGS CORP., 333 LUDLOW ST., NORTH TOWER, 6TH FLOOR, STAMFORD	/s/ Bridget Brown, Attorney-in-Fact	09 Mar 2026	0001689575

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	WGS	Class A Common Stock	Award		+3,404	+8.8%	$88.11^*	42,087	06 Mar 2026	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.

Content

Pursuant to a Subscription Agreement executed on March 6, 2026 between GeneDx Holdings Corp. (the "Issuer") and the reporting person, the reporting person acquired 3,404 shares of the Issuer's Class A common stock directly from the Issuer in an exempt transaction pursuant to Rule 16b-3(d) at a purchase price of $88.11 per share, the closing price of the Issuer's Class A common stock on March 6, 2026.